Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button
arrow_left sharing button
arrow_right sharing button


Integrated Discovery Platform
From Concept to IND

Other Molecular Modalities ​

WuXi Biologics offers extensive design, generation, and discovery of new molecular modalities, including but not limited to: bispecific / multispecific antibodies, ADCs, recombinant proteins, fusion proteins, cytokines, immunocytokines, peptides, nanobodies, antibody fragments, TCR-based antibodies, viral proteins, and other biologics. Our team of experts work with you to establish the best path in optimizing your molecule to its target and for its intended purpose.

Antibody Drug Conjugates (ADCs)


WuXi Biologics offers comprehensive, one-stop in vitro and in vivo characterization services to assist our clients and enable them to discover the ideal ADC candidate to move into CMC development and on to clinical trials.


ADC In Vitro Characterization Platform


Comprehensive biologics screening and characterization throughout the lead drug candidate selection process is provided. We also offer assay development services as required for your specific project needs. ADC in vitro characterization services and methods include:


Antigen-antibody binding methods

  • FACS
  • SPR


Internalization analysis 

  • pHrodo
  • Acid quench
  • Co-localization
  • Time-course


Other critical in vitro characterization evaluations

  • High-throughput and quick cytotoxicity assessment
  • Bystander killing
  • Free-payload release and drug-to-antibody ratio (DAR) stability for serum or plasma samples


For more information including case studies illustrating our in vitro characterization capabilities for ADCs, download this informative flyer:

ADC In Vivo Characterization Platform


Our highly-trained scientists and experts provide the full-spectrum of in vivo characterization services including in vivo efficacy evaluation of therapeutic antibodies, ADCs and other large molecules for the treatment of tumors, autoimmune conditions, inflammatory disease, diabetes and other diseases. Capabilities include:

  • Variety of in vivo efficacy evaluation models using an extensive array of tumor/mouse models


  • Full methodologies for PK profiling validated for consistency and accuracy to detect total antibody, total ADC and free drug using advanced methodologies:
    • LC-MS
    • ELISA
    • MSD: Fc-Fc, Fc-Fab, Fc-Drug


  • High-quality PD evaluation utilizing FACS, ELISA, MSD and IVIS systems.


  • Comprehensive, high-capacity histological evaluations using state-of-the-art instrumentation


For more case studies illustrating our in vivo characterization capabilities for ADCs, download this informative flyer:

Variety of in vivo Efficacy Evaluation Models

WuXi Biologics provides an extensive variety of tumor/mouse models for in vivo efficacy characterization of ADCs.

Learn more about our capabilities for ADC’s:

Fusion Protein


Our Fusion Protein Services include the following. For additional services please Contact Us.


  • Protein generation services
    • Expression level
    • Stability
    • Binding
    • Function
    • Half-life
  • Discovery project



Cytokine/Immunocytokine services are available. For additional services please Contact Us.


  • Protein generation services
    • Expression level
    • Stability
    • Binding
    • Function
    • Half-life
  • Discovery project

Other Protein Design and Engineering Services Available. For additional services please Contact Us.


  • Engineered proteins

    • Virus proteins
    • TCR based therapeutics
    • Peptides
    • Linkers
    • Platform development
  • Design to meet intended purpose
    • Expression level​
    • Stability​
    • Binding
    • Function
    • Half-life
  • Discovery project